It has been found that expression of 15-lipoxygenasc-1(15-LOX-1) and its main product,13-C-hydroxyoctadecadienoic acid (13-S-HODE),are decreased in human colorectal and esophageal cancers and that nonsteroidal anti-inflammatory drugs(NSAIDs) can therspeutically induce 15-LOC-1 expression to trigger apoptosis in those cancer cells independently COX-2.We found that a specific COX-2 inhibitor SC-236 similarly induce apoptosis in gastric cancer cells,although the mechanisms of these effects remain to be defined.In the present study,we tested whether SC-236 induced apoptosis through up-regulation of 15-LOX-1 in gastric cancer cells.We found that,(a) SC-236 inhibited growth of gastric cancer cells mainly by apoptosis induced;(b) SC-236 induced 15-LOX-1 expression and increased endogenous 13-S-HODE product,instead of 15-S-HETE during apoptosis in gastric cancer cells without 15-LOX-1 expression before treatment by SC-236;(c)sc-236 didn't effect expression of COX-1,COX-2,5-LOX and 12-LOX;and (d)15-LOX-1 inhibition suppressed SC-236 induced apoptosis.These findings demonstrated that SC-236 induced apoptosis in gastric cancer cells via up-regulation of 25-LOX-1.They also support the concept that the loss of the proapopotic role of 15-LOX-1 in epithelial cancers is not limited to human colorectal and esophageal cancers.
展开▼
